论文部分内容阅读
全球研发正呈现向亚洲转移的趋势,驱动这一现象的主要原因是研发费用的最优化和创新成果的最大化。身处亚洲的中国和印度在研发模式上具有多样性,制药企业同生物科技公司可分早、中、晚三个阶段进行合作。早期开发合作即利用化学、A D M E-TOX筛选技术、药物活性研究和生化信息
Global R & D is showing a shift to Asia. The main reason driving this is the optimization of research and development costs and the maximization of innovation. In Asia, China and India have diverse R & D modes. Pharmaceutical companies and biotech companies can collaborate in three phases: early, middle and late. Early Development Collaboration that utilizes chemistry, ADME-TOX screening techniques, pharmacological activity studies and biochemical information